Loss is Win for Boston Scientific as Abbot's Xience V bests the Taxus stent

As previously reported, Abbot's Xience V stent outperformed Boston Scientific's Taxus coronary stent in the Spirit III trial. This is excellent news for Abbott. However, as reported previously, Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS™ Everolimus-Eluting Coronary Stent System. PROMUS is designed, studied and manufactured by Abbott and supplied as part of a distribution agreement between the two companies.

A study from JAMA, "SPIRIT III is the first large-scale clinical trial to show that patients
have a lower risk of experiencing a heart attack, cardiac death or
re-treatment when treated with a new stent, XIENCE V, compared to the most
widely used drug eluting stent TAXUS," said Gregg W. Stone, M.D., of the
Columbia University Medical Center; chairman, Cardiovascular Research
Foundation, New York; and principal investigator of the SPIRIT III clinical
trial.

There seems to be plenty of upside for Boston Scientific as a consquequence of this study which demonstrates some performance benefit

Comments

[Medtechobserver]

While it's nice to have for BSX, the Promus>Taxus news is not welcome by the company. They have to pay ABT something like 50% of revenues from Promus, and ABT makes all of them. It will destroy their margins as Taxus gets replaced by the new platform.